Evidence map›Paper›PMID 34271883›Full record

ArticleBMC public health2021

Multi-country cross-sectional study of colonization with multidrug-resistant organisms: protocol and methods for the Antibiotic Resistance in Communities and Hospitals (ARCH) studies.

Aditya Sharma, Ulzii-Orishikh Luvsansharav, Prabasaj Paul, Joseph D Lutgring, Douglas R Call, Sylvia Omulo, Kayla Laserson, Rafael Araos, Jose M Munita, Jennifer Verani and 10 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06044272 (Antimicrobial Resistance Profiles in Healthcare Facilities From Meta State, Colombia), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06044272 completednot on this mapstarted 2023, after this paper: background citation

Antimicrobial Resistance Profiles in Healthcare Facilities From Meta State, Colombia: A Retrospective Observational Study From 2018-2022

TypeobservationalSponsorHospital Departamental de VillavicencioRan2023 to 2024Enrolled10,000ConditionsIncreased Drug ResistanceArmsFactors associated
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Carbapenem-resistantInfection & chemotherapy · 2024
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Using Colonization to Understand the Burden of Antimicrobial Resistance Across Low- and Middle-Income Countries.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  14. High Burden of Intestinal Colonization With Antimicrobial-Resistant Bacteria in Chile: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 6 countries.

Aditya SharmaDivision of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, Office of the Director, 1600 Clifton Rd NE, MS H16-2, Atlanta, GA, 30029, USA.
Ulzii-Orishikh LuvsansharavDivision of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, Office of the Director, 1600 Clifton Rd NE, MS H16-2, Atlanta, GA, 30029, USA.
Prabasaj PaulDivision of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, Office of the Director, 1600 Clifton Rd NE, MS H16-2, Atlanta, GA, 30029, USA.
Joseph D LutgringDivision of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, Office of the Director, 1600 Clifton Rd NE, MS H16-2, Atlanta, GA, 30029, USA.
Douglas R CallPaul G. Allen School for Global Animal Health, Washington State University, 240 SE Ott Road, Pullman, WA, 99164, USA.
Sylvia OmuloPaul G. Allen School for Global Animal Health, Washington State University, 240 SE Ott Road, Pullman, WA, 99164, USA.
Kayla LasersonDivision of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, Office of the Director, 1600 Clifton Rd NE, MS H16-2, Atlanta, GA, 30029, USA.
Rafael AraosInstituto de Ciencias e Innovación en Medicina Universidad del Desarrollo, Av. Las Condes, 12461, Santiago, Chile.
Jose M MunitaInstituto de Ciencias e Innovación en Medicina Universidad del Desarrollo, Av. Las Condes, 12461, Santiago, Chile.
Jennifer VeraniDivision of Global Health Protection, KEMRI Complex, Kenya Office, Mbagathi road off Mbagathi Way, PO Box 606-00621, Nairobi, Kenya.
Fahmida Chowdhuryicddr, b, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka, 1212, Bangladesh.
Syeda Mah-E Muneericddr, b, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka, 1212, Bangladesh.
Andres Espinosa-BodeDivision of Global Health Protection, Central America Region Office, Edificio Instituto de Investigación 2 (II-2), Interior Universidad Del Valle, 18 Avenida 11-37, Vista Hermosa 3, Zona 15, Guatemala City, Guatemala.
Brooke RamayPaul G. Allen School for Global Animal Health, Washington State University, 240 SE Ott Road, Pullman, WA, 99164, USA.
Celia Cordon-RosalesCenter for Health Studies, Universidad del Valle de Guatemala, Guatemala City, Guatemala.
C P Girish KumarNational Institute of Epidemiology, II Main Road, TNHB, Ayapakkam, Chennai, 600 077, India.
Tarun BhatnagarNational Institute of Epidemiology, II Main Road, TNHB, Ayapakkam, Chennai, 600 077, India.
Neil GuptaDivision of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, Office of the Director, 1600 Clifton Rd NE, MS H16-2, Atlanta, GA, 30029, USA.
Benjamin ParkDivision of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, Office of the Director, 1600 Clifton Rd NE, MS H16-2, Atlanta, GA, 30029, USA.
Rachel M SmithDivision of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, Office of the Director, 1600 Clifton Rd NE, MS H16-2, Atlanta, GA, 30029, USA. vih9@cdc.gov.ORCID 0000-0002-8337-1557
Centers for Disease Control and Prevention · USWashington State University · USInternational Centre for Diarrhoeal Disease Research · BDNational Institute of Epidemiology · INUniversidad del Desarrollo · CLUniversidad del Valle de Guatemala · GTKenya Medical Research Institute · KE

Funding

ACL HHS U01GH002241CDC HHS #75D301-18C-02925CDC HHS GH001297CDC HHS GH001859CDC HHS GH002143CGH CDC HHS U01 GH002143CGH CDC HHS U01 GH002241
6 · The paper itself

Abstract

backgroundAntimicrobial resistance is a global health emergency. Persons colonized with multidrug-resistant organisms (MDROs) are at risk for developing subsequent multidrug-resistant infections, as colonization represents an important precursor to invasive infection. Despite reports documenting the worldwide dissemination of MDROs, fundamental questions remain regarding the burden of resistance, metrics to measure prevalence, and determinants of spread. We describe a multi-site colonization survey protocol that aims to quantify the population-based prevalence and associated risk factors for colonization with high-threat MDROs among community dwelling participants and patients admitted to hospitals within a defined population-catchment area.

methodsResearchers in five countries (Bangladesh, Chile, Guatemala, Kenya, and India) will conduct a cross-sectional, population-based prevalence survey consisting of a risk factor questionnaire and collection of specimens to evaluate colonization with three high-threat MDROs: extended-spectrum cephalosporin-resistant Enterobacteriaceae (ESCrE), carbapenem-resistant Enterobacteriaceae (CRE), and methicillin-resistant Staphylococcus aureus (MRSA). Healthy adults residing in a household within the sampling area will be enrolled in addition to eligible hospitalized adults. Colonizing isolates of these MDROs will be compared by multilocus sequence typing (MLST) to routinely collected invasive clinical isolates, where available, to determine potential pathogenicity. A colonizing MDRO isolate will be categorized as potentially pathogenic if the MLST pattern of the colonizing isolate matches the MLST pattern of an invasive clinical isolate. The outcomes of this study will be estimates of the population-based prevalence of colonization with ESCrE, CRE, and MRSA; determination of the proportion of colonizing ESCrE, CRE, and MRSA with pathogenic characteristics based on MLST; identification of factors independently associated with ESCrE, CRE, and MRSA colonization; and creation an archive of ESCrE, CRE, and MRSA isolates for future study. DISCUSSION: This is the first study to use a common protocol to evaluate population-based prevalence and risk factors associated with MDRO colonization among community-dwelling and hospitalized adults in multiple countries with diverse epidemiological conditions, including low- and middle-income settings. The results will be used to better describe the global epidemiology of MDROs and guide the development of mitigation strategies in both community and healthcare settings. These standardized baseline surveys can also inform future studies seeking to further characterize MDRO epidemiology globally.

Indexed as

Methicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAdultBangladeshChileCross-Sectional StudiesDrug Resistance, Multiple, BacterialGuatemalaHospitalsHumansIndiaKenyaMultilocus Sequence TypingPrevalenceAntimicrobial resistanceGlobal health securityMDRO

Identifiers

PMID34271883
PMCPMC8285890
OpenAlexW3182878466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.